articleTop 1% cited

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

The Lancet Oncology · 2011 · Vol. 13(1) · pp. 25–32

Luca Gianni✉(Medica (Italy))Tadeusz Pieńkowski(Centrum Onkologii)Young‐Hyuck Im(Samsung Medical Center)Laslo Roman(Leningrad Regional Cancer Center)Ling‐Ming Tseng(Taipei Veterans General Hospital)Mei-Ching Liu(Koo Foundation Sun Yat-Sen Cancer Center)Aňa Lluch(Universitat de València)Elżbieta Starosławska(St. John's University)Juan de la Haba-Rodríguez(Hospital Universitario Reina Sofía)Seock‐Ah Im(Seoul National University Hospital)José Luiz Pedrini(Hospital Nossa Senhora da Conceição)Brigitte Poirier(Hôpital du Saint-Sacrement)Paolo Morandi(Ospedale San Bortolo)Semiglazov Vf(Institute of Oncology NN Petrov)Vichien Srimuninnimit(Siriraj Hospital)Giulia Bianchi(Fondazione IRCCS Istituto Nazionale dei Tumori)Tania SzadoJayantha Ratnayake(Roche (United Kingdom))Graham Ross(Roche (United Kingdom))Pinuccia Valagussa(Fondazione Michelangelo)

View via DOI Publisher page

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Peptidase Inhibition and AnalysisPertuzumabTrastuzumabDocetaxelMedicineInternal medicineClinical endpointBreast cancerOncologyPopulationChemotherapy

MeSH terms

TrastuzumabDocetaxelAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAsiaBrazilBreast NeoplasmsCanadaEuropeFemaleHumansInflammationMastectomy

Citations

2,312

FWCI

60.97

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Effects of Age on the Detection and Management of Breast Cancer